365 matches for your search in the start-up spotlight
rss
NEOsphere Biotechnologies combines world-class mass spectrometry with expert data analysis to systematically create broad pipelines of novel degrader targets at scale and advance our partners’ targeted protein degradation (TPD) drug discovery programs at all stages. Our unique target and E3 ...
SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics). Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for ...
CasInvent Pharma was established in 2020 as a spin-off of Masaryk University (MU) in cooperation with the investment partner i&i Prague, s.r.o. (Ltd). The mission of the company is to develop new therapeutic options for the treatment resistant tumors. The CasInvent platform is based on the use of ...
DISCO Pharma, operating out of Cologne, Germany and Schlieren, Switzerland, employs a disruptive scalable technology to map the surfaceome of cancer cells and develop first-in-class cancer drugs. With the advent of new cell-surface, target-directed therapeutic modalities (including ADCs and ...
PharmaKure, a clinical stage pharmaceutical company is targeting neurodegenerative diseases including Alzheimer’s and Parkinson’s Diseases and other rare diseases. The company’s propriety technology allows the diagnosis and monitoring of drug treatment for patients using blood-based ...
Amyl Therapeutics has developed a novel mechanism to conformationally bind to the amyloid fold of toxic protein aggregates of various types, causing neurodegenerative diseases or systemic amyloidosis diseases. The pan-amyloid binding and amyloid fibril remodeling capabilities of Amyl ...
Bioxodes specializes in the development of novel therapies for the prevention and treatment of thrombotic and inflammatory diseases. Since its founding in 2013, Bioxodes has developed its own flagship program based around its Ir-CPI molecule. Ir-CPI is a first-in-class drug candidate aimed at ...
DIOSynVax customises vaccine antigen design to maximise the protection that vaccines can provide worldwide against existing and future viruses. Grounded firmly in virus structure and evolution, our method is patent protected, combining computational biology with in vitro and in vivo validation, ...
aidCURE AG is a German biotechnology company founded by scientists and drug developers to help the large number of patients whose lives are affected by rheumatoid arthritis and other autoimmune diseases. aidCURE is associated with the Fraunhofer Institute for Translational Medicine and ...
SOLID Therapeutics is an early-stage oncology company which is based on research at University of Copenhagen joining expertise in metabolite GPCR structure-based drug discovery in the Schwartz-Frimurer labs at the Novo Nordisk Foundation (NNF) Center for Basic Metabolic Research (CBMR) with the ...
